FightMND Supports ALS Research on Inflammasome Blocker RRx-001
EpicentRx has been awarded funding from FightMND to study how well RRx-001, its lead small molecule, may protect…
Articles by Margarida Maia, PhD
First Patients Dosed in Eye Study of Tracer for ALS Diagnosis
The first patients have been dosed in a Phase 1/2a clinical study that’s testing AMDXP-2011P for its ability to trace…
App Can Help Monitor ALS Progression in Patients From Home
Using a digital tool to assess disease severity remotely is feasible for people with amyotrophic lateral sclerosis (ALS) and…
Stem Cell-based Therapy to Produce GDNF Found Safe in Human Trial
Stem cells engineered to mature into nerve-supporting cells that produce GDNF — a key factor for motor neuron survival —…
ALS Patients Have Higher Lead Levels in Blood, Review Study Finds
People with amyotrophic lateral sclerosis (ALS) have significantly higher blood levels of lead, a toxic heavy metal, than those…
Pasithea Receives Funding to Develop Antibodies for ALS
Pasithea Therapeutics has gained access to AU$1 million (about $694,000) to further its research into anti-integrin antibodies as potential…
AI Finds New Potential Targets for ALS Treatment in Patient Data
PandaOmics, an artificial intelligence (AI) platform that looks at vast amounts of data to find “druggable” molecules, has identified…
Corestem Shares Protocol for Long-term NeuroNata-R Trial
Corestem is still enrolling participants in its Phase 3 clinical trial of NeuroNata-R (lenzumestrocel), a stem cell therapy…
FDA Shares Plan for ALS, Other Neurodegenerative Diseases
The U.S. Food and Drug Administration (FDA) has published on its website a five-year action plan meant to help advance…
PrimeC Therapy Added to Standard Care Gets ALS Biomarkers Down
NeuroSense Therapeutics’ combination therapy PrimeC led to a significant decline in certain biomarkers of amyotrophic lateral sclerosis (ALS) when…